Get the Stockscreener App
62.40
1.29%
0.845
Uniqure N V stock is traded at $62.40, with a volume of 1.32M.
It is up +1.29% in the last 24 hours and up +278.22% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$61.55
Open:
$61.81
24h Volume:
1.32M
Relative Volume:
0.43
Market Cap:
$3.42B
Revenue:
$14.34M
Net Income/Loss:
$-199.00M
P/E Ratio:
-15.92
EPS:
-3.92
Net Cash Flow:
$-183.51M
1W Performance:
+17.84%
1M Performance:
+278.22%
6M Performance:
+598.21%
1Y Performance:
+1,004%
1-Day Range:
$61.45
$63.57
1-Week Range:
$50.80
$65.12
52-Week Range:
$5.35
$65.12
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
62.30 | 3.79B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.64 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.46 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.32 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.07 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
Using Bollinger Bands to evaluate uniQure N.V.Index Update & Technical Pattern Based Buy Signals - newser.com
Can uniQure N.V. stock hit analyst price targetsBull Run & Stepwise Swing Trade Plans - newser.com
Is uniQure N.V. stock trading at a premium valuationJuly 2025 Closing Moves & Weekly Top Gainers Alerts - newser.com
How institutional buying supports uniQure N.V. stockJuly 2025 Setups & Expert Curated Trade Setups - newser.com
Is uniQure N.V. stock a safe investment in uncertain marketsTrade Risk Report & Long-Term Safe Investment Plans - newser.com
uniQure NV Hits New 52-Week High of $61.79, Surging 1014.68% - Markets Mojo
uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is uniQure’s Rally Justified After Positive Huntington’s Disease Therapy Data? - Yahoo Finance
Jim Cramer on uniQure: “This One Has Too Many Questions for Me Up Here” - MSN
Trend analysis for uniQure N.V. this week2025 Momentum Check & Expert Verified Movement Alerts - newser.com
Will uniQure N.V. see short term momentumBreakout Watch & Verified Technical Trade Signals - newser.com
Will uniQure N.V. (UQ1) stock beat value stocksDay Trade & AI Powered Market Trend Analysis - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for uniQure (NASDAQ:QURE) - MarketBeat
Is uniQure’s Stock Poised for a Comeback? - StocksToTrade
Price momentum metrics for uniQure N.V. explainedBreakout Watch & Technical Entry and Exit Tips - newser.com
Developing predictive dashboards with uniQure N.V. dataWeekly Trade Report & Verified Stock Trade Ideas - newser.com
Biopharma Financing Veers Toward Optimism, But Cell And Gene Therapies Left Behind - insights.citeline.com
uniQure: Further Upside Likely As The Opportunity Becomes Better Understood (QURE) - Seeking Alpha
uniQure NV Hits Day High with 9.47% Surge Amid Strong Intraday Performance - Markets Mojo
uniQure (NASDAQ:QURE) Sets New 12-Month HighTime to Buy? - MarketBeat
Uniqure NV stock hits 52-week high at 60.84 USD By Investing.com - Investing.com Nigeria
RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $65 - 富途牛牛
Uniqure NV stock hits 52-week high at 60.84 USD - Investing.com
United States Adeno-Associated Virus (AAV) Vectors - openPR.com
HC Wainwright Analysts Lift Earnings Estimates for uniQure - MarketBeat
UniQure’s Unexpected Surge: Analyzing QURE’s Performance - timothysykes.com
uniQure (NASDAQ:QURE) Shares Up 7.7% Following Analyst Upgrade - MarketBeat
HC Wainwright Issues Positive Forecast for uniQure Earnings - MarketBeat
uniQure’s Huntington’s gene therapy holds blockbuster potential, says analyst - The Pharma Letter
Why uniQure (QURE) Is Up After Strong AMT-130 Data and $475 Million in New Funding - Sahm
uniQure (NASDAQ:QURE) Price Target Raised to $110.00 at HC Wainwright - MarketBeat
HC Wainwright & Co. Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
uniQure stock price target raised to $110 from $70 at H.C. Wainwright - Investing.com
uniQure (QURE) Receives Boosted Price Target from HC Wainwright & Co. | QURE Stock News - GuruFocus
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $110 - 富途牛牛
Is uniQure N.V. (UQ1) stock nearing a technical breakout2025 Bull vs Bear & Consistent Return Investment Signals - newser.com
Is uniQure N.V. meeting your algorithmic filter criteriaJuly 2025 Catalysts & Smart Investment Allocation Insights - newser.com
Is uniQure N.V. showing signs of accumulation2025 Biggest Moves & Free Safe Capital Growth Stock Tips - newser.com
Is uniQure N.V. (UQ1) stock a top dividend aristocrat candidate2025 Institutional Moves & Weekly High Return Stock Forecasts - newser.com
Will uniQure N.V. bounce back from current supportEarnings Beat & Safe Entry Zone Identification - newser.com
uniQure N.V. stock retracement – recovery analysisDay Trade & Weekly Return Optimization Plans - newser.com
Measuring uniQure N.V.’s beta against major indices2025 Growth vs Value & Safe Entry Momentum Stock Tips - newser.com
QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop - MarketBeat
Morgan Lewis Advises UniQure in $345 Million Public Equity Offering – News - Morgan Lewis
Visual trend scoring systems applied to uniQure N.V.Quarterly Performance Summary & High Accuracy Swing Entry Alerts - newser.com
How to build a custom watchlist for uniQure N.V.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Uniqure N V Stock (QURE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director |
Sep 24 '25 |
Sale |
41.46 |
226,316 |
9,382,473 |
651,454 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 26 '25 |
Option Exercise |
5.37 |
15,000 |
80,550 |
232,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 24 '25 |
Option Exercise |
13.03 |
3,000 |
39,090 |
220,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 26 '25 |
Sale |
55.00 |
15,000 |
825,000 |
217,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 24 '25 |
Sale |
40.04 |
3,000 |
120,120 |
217,730 |
1.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):